Navigation Links
Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
Date:9/6/2011

NEW YORK, Sept. 6, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the following September 2011 investor conferences:

Stifel Nicolaus Healthcare Conference (Boston, MA)
Wednesday, September 7, 2011
10:55am ET

Rodman & Renshaw Annual Global Investment Conference (New York, NY)
Monday, September 12, 2011
10:50am ET

UBS Global Life Sciences Conference (New York, NY)
Tuesday, September 20, 2011
11:00am ET

JMP Securities Sixth Annual Healthcare Conference (New York, NY)
Tuesday, September 27, 2011
10:30am ET

Each of the presentations will be live audio webcast, and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. Archived versions of each webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects other signal transduction pathways, including the JNK pathway, believed to be associated with cell death, growth, differentiation and survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA). Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2011 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
3. Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
4. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
5. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
6. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
8. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
9. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
10. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
11. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... and HAMBURG, Germany , February 22, 2017 ... precision oncology headquartered in Hamburg, Germany and ... research institution, announced today a collaboration to support the first Indian ... research. ... Indivumed signed an agreement with an initial three-year term. The collaboration ...
(Date:2/22/2017)... , Feb. 22, 2017  Soligenix, Inc. (Nasdaq: ... a late-stage biopharmaceutical company focused on developing and ... is an unmet medical need, announced today that ... granted a European patent for the treatment of ... methods of treatment of skin conditions, complements the ...
(Date:2/21/2017)... Feb. 21, 2017 Mass Spectrometer Market: ... http://www.reportlinker.com/p04711309-summary/view-report.html This report on mass ... future prospects of the market globally. The stakeholders ... in the manufacture and commercialization of various mass ... entrants planning to enter this market. This report ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... Becker’s Spine Review, the leading ... Michigan neurosurgeon Jay Jagannathan, M.D., as a “Spine Surgeon to Know.” http://www.beckersspine.com/spine-leaders/item/35348- ... in Michigan performing minimally invasive back surgery that often results in less post-operative ...
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five percent of ... report that family members or friends have also commented about their poor hearing. ... wear hearing aids. One reason, suggested by 89 percent of American respondents, is ...
(Date:2/22/2017)... ... ... Social media marketing is transitioning from a singular person activity to a collaborative ... this insight and more in its latest episode of its Brains Over Brawn podcast. ... social media strategist and partner of the digital firm Med|Ed Digital Jessica Columbo. Jessica ...
(Date:2/22/2017)... ... February 22, 2017 , ... In ... advocates stress that the patient context (age, illness and life choices) should be ... mitigate their occurrence. In addition, all too often, studies regarding health ...
(Date:2/21/2017)... Australia (PRWEB) , ... February 22, 2017 , ... Author ... it is valuable for every household and family to know all about it for ... publishing world with the release of “ Detox, Digestive and Wellness Solutions ” (published ...
Breaking Medicine News(10 mins):